脂蛋白相关磷脂酶A2与动脉粥样硬化及冠心病关系的研究进展

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (0 KB) HTML (42 KB)
Export: BibTeX | EndNote (RIS)

Abstract Cardiovascular disease (CVD) has become a serious disease endangering human health,and its morbidity and mortality remain high in China,which brings great pain and burden to people′s lives.In recent years,with the indepth study of atherosclerosis and coronary heart disease,lipoprotein-associated phospholipase A2 (Lp-PLA2),as a newly discovered inflammatory marker,has attracted more and more attention due to its involvement in its occurrence and development,and now it is considered to be a variable predictor of CVD risk.After collating the related literature in recent years,this paper mainly reviews the structural characteristics and influencing factors of Lp-PLA2 and its relationship with atherosclerosis and coronary heart disease.

Key words： Atherosclerosis Coronary heart disease Atherosclerotic plaque Phospholipase A2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Zhi-Hong1
	2
	SHEN Qiang1
	2▲

Cite this article:

LI Zhi-Hong1,2,SHEN Qiang1, et al. Research progress on the relationship between lipoprotein-associated phospholipase A2 and atherosclerosis and coronary heart disease[J]. 中国当代医药, 2020, 27(31): 21-25.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I31/21

[1]	Li H，Sun K，Zhao R，et al.Inflammatory biomarkers of coronary heart disease[J].Front Biosci （Schol Ed），2018，10：185-196.
[2]	Tousoulis D，Kampoli A，Papageorgiou N，et al.Pathophysiology of atherosclerosis： the role of inflammation[J].Curr Pharm Des，2011，17（37）：4089-4110.
[3]	Dennis EA，Cao J，Hsu YH，et al.Phospholipase A2 enzymes：physical structure，biological function，disease implication，chemical inhibition，and therapeutic intervention[J].Chem Rev，2011，111（10）：6130-6185.
[4]	Rosenson RS，Stafforini DM.Modulation of oxidative stress，inflammation，and atherosclerosis by lipoprotein-associated phospholipase A2[J].J Lipid Res，2012，53（9）：1767-1782.
[5]	Goncalves I，Edsfeldt A，Ko NY，et al.Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation[J].Arterioscler Thromb Vasc Biol，2012，32（6）：1505-1512.
[6]	熊燕华，张大庆.《脂蛋白相关磷脂酶A2 临床应用中国专家建议》解读[J].中国医药导刊，2018，20（3）：138-145.
[7]	Seyedi S，Mottaghi A，Mirmiran P，e t al.The relationship between dietary patterns and lipoprotein-associated phospholipase A2 levels in adults with cardiovascular risk factors：Tehran Lipid and Glucose Study[J].J Res Med Sci，2020，25：3.
[8]	Packard CJ，O′Reilly DS，Caslake MJ，et al.Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease.West of Scotland Coronary Prevention Study Group[J].N Engl J Med，2000，343（16）：1148-1155.
[9]	Ge PC，Chen ZH，Pan RY，et al.Synergistic Effect of Lipoprotein-Associated Phospholipase A2 with Classical Risk Factors on Coronary Heart Disease：A Multi-Ethnic Study in China[J].Cell Physiol Biochem，2016，40（5）：953-968.
[10]	Wang X，Chen Q，Xu Y，et al.Risk factors of atherosclerotic tissue types in single-vessel and intermediate coronary lesions：a cross-sectional study[J].Lipids Health Dis，2017，16（1）：63.
[11]	Wang C，Fang X，Hua Y，et al.Lipoprotein -Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China[J].Angiology，2018，69（1）：49-58.
[12]	Li D，Zhao L，Yu J，et al.Lipoprotein-associated phospholipase A2 in coronary heart disease：Review and metaanalysis[J].Clin Chim Acta，2017，465：22-29.
[13]	Li D，Wei W，Ran X，et al.Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population：A systematic review and meta-analysis[J].Clin Chim Acta，2017，471：38-45.
[14]	Li J，Wang H，Tian J，et al.Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome[J].Medicine （Baltimore），2018，97（28）：e11517.
[15]	王凌，谢伟贤，邓爱红.血浆脂蛋白相关磷脂酶A2 水平在冠心病患者严重程度评估中的应用价值[J].慢性病学杂志，2019，20（3）：358-360.
[16]	Lu J，Niu D，Zheng D，et al.Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin Ⅲfor acute coronary syndrome risk[J].Biomed Rep，2018，9（6）：517-522.
[17]	Yang F，Ma L，Zhang L，et al.Association between serum lipoprotein-associated phospholipase A2，ischemic modified albumin and acute coronary syndrome：a cross-sectional study[J].Heart Vessels，2019，34（10）：1608-1614.
[18]	Yang L，Liu Y，Wang S，et al.Association between Lp-PLA2 and coronary heart disease in Chinese patients[J].J Int Med Res，2017，45（1）：159-169.
[19]	王娜，刘和俊.脂蛋白相关磷脂酶A2与早发冠心病的相关性分析[J].中国实用医药，2020，15（14）：14-16.
[20]	Ma CY，Xu ZY，Wang SP，et al.Change of Inflammatory Factors in Patients with Acute Coronary Syndrome[J].Chin Med J （Engl），2018，131（12）：1444-1449.
[21]	Li J，Zhou Z，Niu X，et al.Lipoprotein-Associated Phospholipase A2 in Cardiac Disease：a Potential Early Biomarker of Unstable Coronary Artery Disease[J].Clin Lab，2020，66（5）.doi：10.7754/Clin.Lab.2019.190719.
[22]	Fleming I，Mohamed A，Galle J，et al.Oxidized low-density lipoprotein increases superoxide production by endothelial nitric oxide synthase by inhibiting PKCalpha[J].Cardiovasc Res，2005，65（4）：897-906.
[23]	Yang L，Cong HL，Wang SF，et al.AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis[J].Exp Ther Med，2017，13（4）：1622-1629.
[24]	Wu C，Zhou T，Zhou Y，et al.Association of Serum Lipoprotein-Associated Phospholipase A2 and A379V Gene Polymorphisms with Carotid Plaques[J].Genet Test Mol Biomarkers，2020，24（3）：131-137.
[25]	Heriansyah T，Nafisatuzzamrudah N，Aini FN，et al.Reduction in Vasa Vasorum Angiogenesis by Lp-PLA2 Selective Inhibitor Through The HIF-1α and VEGF Expression Under Dyslipidemic Conditions in Atherosclerosis Pathogenesis[J].Cardiovasc Hematol Agents Med Chem，2018，16（2）：114-119.
[26]	Johnson JL，Shi Y，Snipes R，et al.Effect of darapladib treatment on endarterectomy carotid plaque lipoproteinassociated phospholipase A2 activity：a randomized，controlled trial[J].PLoS One，2014，9（2）：e89034.
[27]	Prasad M，Lennon R，Barsness GW，et al.Chronic inhibition of lipoprotein-associated phospholipase A2 does not improve coronary endothelial function：A prospective，randomized-controlled trial[J].Int J Cardiol，2018，253：7-13.
[28]	Kokotou MG，Limnios D，Nikolaou A，et al.Inhibitors of phospholipase A2 and their therapeutic potential：an update on patents （2012-2016）[J].Expert Opin Ther Pat，2017，27（2）：217-225.
[29]	Santoso A，Heriansyah T，Rohman MS.Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases：Is there any Spacious Room to Prove the Causation?[J].Curr Cardiol Rev，2020，16（1）：3-10.
[30]	Maiolino G，Bisogni V，Rossitto G，et al.Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications[J].World J Cardiol，2015，7（10）：609-620.